Differentiation of Lung Cancer

Roig et al (Anticancer Research, 1993, vol. 13, pp. 2457-2463. Burke et al (Human Pathology, 1999, vol. 30, pp. 158–167).* 60/121,124. Guddo et al (J Clin Pathol, 1998, vol. 51, pp. 667-671).* Malusecka et al (Anticancer Research, 2001, 21, vol. 1015-1021).* Dessy et al (Virchows Archive, Mar 2000, vol. 436, pp. 289-296).* Puglisi et al (Cancer Letters, 2001, vol. 162, pp. 97-103).* Schlom (Monoclonal Antibodies, In: Molecular Foundations of Oncology, 1991, pp. 95–134).* Flam et al., “Immunohistochemical markers defined by monoclonal antibodies and response to bacillus Cal mette-Gueriri endovesical immunotherapy for Superficial bladder tumors”, Abstract, European Urology, pp. 338-342, vol. 17, No. 4. Duray et al., “Immunohistochemical phenotyping of malig nant melanoma. A procedure whose time has come in pathology practice', Abstract, Pathology Annual, pp. 351-377, vol. 25 Pt. 2, 1990. Gazdar et al., “Biological, Molecular, and Clinical Markers for the Diagnosis and Typing of Lung Cancer, Abstract, Immunol. Ser, pp. 453-468, vol. 53, 1990. Terada et al., “N-Ras Gene-Mutations in Childhood Acute Non-Lymphoblastic Leukemia', Abstract, Leukemia Research, pp. 935–941, vol. 15, No. 10, 1991. Imamura et al., “Detection of High-Incidence of N-Ras Oncogene Point Mutations in Acute Myelogenous Leuke mia', Abstract, American Journal of Hematology, pp. 151–153, vol. 43, No. 2, Jun. 1993. Wood et al., “Immunocytochemical and Differentiation of Reactive Hyperplasia from Follicular Lymphoma Using Monoclonal Antibodies to Cell-Surface and Proliferation Related Markers”, Abstract, Applied Immunohistochemis try, pp. 48-53, vol. 2, Nol. 1, Spring 1994. Jacquemier et al., “P53 Immunochemical Analysis in Breast Cancer with 4 Monoclonal-Antibodies-Comparison of Stat ing and PCR-SSCP Results”, Abstract, British Journal of Cancer, pp. 846-852, vol. 69, No. 5, May 1994. Granberg et al., “Prognostic markers in bronchial carcinoid tumors”, Abstract, Proc Annu Meet Am ASSoc Cancer Res, vol. 38, A774, 1997. Pastorino et al., “Immunochemical markers in Stage I lung cancer: relevance to prognosis, Abstract, Journal of Clinical Oncology, pp. 2858-2865, vol. 15, No. 8, Aug. 1997. Harpole et al., “A biological risk model for Stage I lung cancer: Immunohistochemcial analysis of 408 patients with the use of ten molecular markers', Abstract, Journal of Thoracic and Cardiovascular Surgery, pp. 736–742, vol. 117, No. 4, Apr. 1999.